

APR 18 2001

04-19-0017 Rec'd PCT/PTO 1.8 APR 2001

Form PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney's Docket Number 46309-257438
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known, see 37 CFR 1.5) 09/807809
International Application No. PCT/GB00/03144	International Filing Date 14 August 2000 (14.08.2000)	Priority Date Claimed 18 August 1999 (18.08.1999)
Title of Invention BACULOVIRUS EXPRESSION SYSTEM		
Applicant(s) for DO/EO/US POSSEE, Robert David; KING, Linda Anne		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.14. <input type="checkbox"/> A substitute specification.15. <input type="checkbox"/> A change of power of attorney and/or address letter.16. <input type="checkbox"/> Other items or information:		
Express Mail Label No.EL329505184US Page 1 of 2		Date: April 18, 2001

U.S. Application No. (if known, see 37 CFR 1.5) 09/807809	International Application No. PCT/GB00/03144	Attorney's Docket Number 46309-257438
---	---	--

17. ☒ The following fees are submitted: CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

<input type="checkbox"/> ENTER APPROPRIATE BASIC FEE AMOUNT =	\$840	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input checked="" type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$130	

Claims	Number Filed	Number Extra	Rate		
Total claims	24 - 20 =	4	x 18.00	\$72	
Independent Claims	1 - 3 =	0	x 78.00	\$0	
Multiple Dependent Claims (if applicable)			+ 260.00	\$0	
TOTAL OF ABOVE CALCULATIONS =				\$1,042	
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status.				\$0	
SUBTOTAL =				\$1,042	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$0	
TOTAL NATIONAL FEE =				\$1,042	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$0	
TOTAL FEES ENCLOSED =				\$1,042	
				Amount to be refunded:	\$
				charged:	\$


a. ☒ A check in the amount of \$1,042 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 11-0855 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 11-0855. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 John K. McDonald, Ph.D.
 Kilpatrick Stockton, LLP
 2400 Monarch Tower, 3424 Peachtree Road, N.E.
 Atlanta, Georgia 30326
 Telephone: 404-949-2400


 John K. McDonald, Ph.D., 42,860

Page 2 of 2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Possee, Robert David

King, Linda Anne

Serial No.: To be Assigned
National Phase of PCT/GB00/03144

Examiner: To be assigned

Filed: Concurrently herewith

Art Unit: To be assigned

For: BACULOVIRUS EXPRESSION
SYSTEM

PRELIMINARY AMENDMENT UNDER § 1.115 AND § 1.121

Box Patent Application
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to examining the present application, please enter the following Amendments.

AMENDMENT

IN THE CLAIMS

Please cancel Claims 1-26 without prejudice or disclaimer.

Please add Claims 27-50.

27: (New) A method for cloning a gene comprising the steps of:

(i) providing a replication-deficient baculovirus vector;


(ii) providing a rescue vector encoding,

(a) a nucleic acid sequence which is capable of restoring replication in

the replication-deficient baculovirus vector, and

(b) at least one gene to be cloned;

I hereby certify that this correspondence is being deposited with the United States Postal Service as **Express**
Mail No. EL329505184US addressed to: Assistant Commissioner of Patents, Box Patent Application, Washington,
DC, 20231, on April 18, 2001.


John K. McDonald, Ph.D. - Reg. No 42,860

(iii) causing the replication-deficient baculovirus vector and rescue vector to recombine to produce a replication-enabled baculovirus vector comprising the at least one gene to be cloned; and

(iv) growing the replication-enabled baculovirus vector within a suitable invertebrate cell.

28. (New) A method according to claim 27, wherein the invertebrate cell is an insect cell.

29. (New) A method according to claim 27, wherein the replication-deficient baculovirus vector lacks a functional gene necessary for viral replication and the rescue vector comprises a gene necessary for restoring the functional gene.

30. (New) A method according to claim 28, wherein the replication-deficient baculovirus vector lacks a functional gene necessary for viral replication and the rescue vector comprises a gene necessary for restoring the functional gene.

31. (New) A method according to claim 29, wherein the functional gene is selected from *lef-1*, *lef-2*, *lef-3*, *lef-4*, *lef-5*, *lef-6*, *lef-7*, *lef-8*, *lef-9*, *lef-10*, *lef-11*, *lef-12*, *dnapol*, *pl43*, *p35*, *ie-1*, *ie-2*, *p47*, *ORF1629* and *pp31*, or a functional fragment or mutation thereof.

32. (New) A method according to claim 30, wherein the functional gene is selected from *lef-1*, *lef-2*, *lef-3*, *lef-4*, *lef-5*, *lef-6*, *lef-7*, *lef-8*, *lef-9*, *lef-10*, *lef-11*, *lef-12*, *dnapol*, *pl43*, *p35*, *ie-1*, *ie-2*, *p47*, *ORF1629* and *pp31*, or a functional fragment or mutation thereof.

33. (New) A method according to claim 31, wherein the functional gene is *lef-2* or a functional fragment or mutation thereof.

34. (New) A method according to claim 32, wherein the functional gene is *lef-2* or a functional fragment or mutation thereof.

35. (New) A method according to claim 27, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

36. (New) A method according to claim 28, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

37. (New) A method according to claim 29, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

38. (New) A method according to claim 30, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

39. (New) A method according to claim 31, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

40. (New) A method according to claim 32, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

41. (New) A method according to claim 33, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

42. (New) A method according to claim 34, wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.

43. (New) A method according to claim 35, wherein the intermediate host is a yeast cell or a bacterial cell.

44. (New) A method according to claim 36, wherein the intermediate host is a yeast cell or a bacterial cell.

45. (New) A method according to claim 37, wherein the intermediate host is a yeast cell or a bacterial cell.

46. (New) A method according to claim 38, wherein the intermediate host is a yeast cell or a bacterial cell.

47. (New) A method according to claim 39, wherein the intermediate host is a yeast cell or a bacterial cell.


48. (New) A method according to claim 40, wherein the intermediate host is a yeast cell or a bacterial cell.

49. (New) A method according to claim 41, wherein the intermediate host is a yeast cell or a bacterial cell.

50. (New) A method according to claim 42, wherein the intermediate host is a yeast cell or a bacterial cell.

Please charge any additional fees, or credit any overpayment, to Deposit Account 11-0855.

Respectfully submitted,



John K. McDonald, Ph.D.
Reg. No. 42, 860

KILPATRICK STOCKTON LLP
2400 Monarch Tower
3424 Peachtree Road, N. E.
Atlanta, Georgia 30326
404-949-2470
Our Docket: 23890-257438 (46309-257438)

09/807 809

BACULOVIRUS EXPRESSION SYSTEM

The invention relates to a method for cloning a gene, to replication deficient baculovirus vectors and rescue vectors for use in the method, to cells comprising such vectors and to kits comprising such vectors.

Baculoviruses have been isolated from a number of invertebrates. Most examples have been found in insect species, but there are some reports of baculoviruses, which are pathogenic for crustacea. Baculovirus infections have been described in over 600 species of insects including Lepidoptera, Hymenoptera, Diptera and Coleoptera. Baculoviruses and their use as expression vectors are discussed in the book by King, L.A and Possee, R.D. "The Baculovirus Expression System. A Laboratory Guide" (Chapman and Hall, 1992).

Baculoviruses have a large, double stranded covalently closed circular DNA genome of between 88 and 180 kilobase pairs (kbp). This associates with a highly basic (arginine-rich) protein of 6.5 kiloDaltons (kDa), within a rod-shaped nucleocapsid, which contains a 39 kDa capsid protein. Other structural components almost certainly remain to be identified. The size of the virus genome determines the length of the nucleocapsid, which may be 200-400 nm.

The nucleocapsids are further packaged within a lipoprotein envelope to form a virus particle or virion. These structures may be occluded within a crystalline matrix or polyhedron consisting largely of a single protein (polyhedrin) of about 30 kDa, and form in the nucleus of infected cells. Polyhedra are large structures ranging in size from 1-15 μ m in diameter and with an outer polysaccharide envelope, which appears to confer additional strength and protection.

Baculoviruses are usually named after the host from which they are isolated. For example, the baculovirus isolated from alfalfa looper was designated *Autographa californica* (Ac)

MNPV. However, baculoviruses which are almost identical to AcMNPV have been found in *Trichoplusia ni*, *Galleria mellonella* and *Rachiplusia ou*. The AcMNPV has been extensively studied at the molecular level largely because of its efficient replication in cell culture. In consequence, it was a logical example to be exploited as an expression vector. Cells derived from *Spodoptera frugiperda* or *Trichoplusia ni* are normally used as the host for propagating the virus. It should be mentioned, however, that other baculovirus expression vectors are known, for example from *Bombyx mori* (silkworm) (Bm) NPV. This latter system, while particularly useful for producing recombinant proteins in silkworm larvae, which are easily reared and handled, has not achieved such widespread popularity as the AcMNPV system.

Baculoviruses are used as expression vectors by inserting genes from other species (e.g. humans, other vertebrates, plants, bacteria and viruses) into the virus genome. They are positioned under the control of a very strong baculovirus gene promoter (eg. polyhedrin) to make a recombinant virus. This promoter drives expression of the foreign gene to make messenger RNA, which in turn makes protein in the recombinant virus-infected cell. The advantage of using this system is that the level of protein generated in the virus-infected cells may be several-fold higher than that achieved in the normal environment in which the protein is made. The function of the recombinant protein may subsequently be studied within the baculovirus-infected cell or after isolation of the product. The baculovirus expression system is widely used in industry and other research laboratories world-wide. In addition to the high levels of recombinant protein attained, the system is also popular because the material produced is usually biologically active. This is frequently a consequence of correct post-translational modification of the recombinant protein after it has been translated from the mRNA on insect cell ribosomes.

One of the limitations of the baculovirus expression system is that the process of inserting foreign genes into the virus genome is time consuming and labour intensive. Currently, two major methods are used. In the first, the baculovirus genome is maintained in *Escherichia coli* and foreign genes are inserted via a process of transposon mutagenesis after introducing another plasmid (the transfer vector) into the bacterial cell (Luckow *et al.*, 1993). After recovering virus DNA from amplified bacterial cells, it is used to infect insect

cells to produce a recombinant virus, which is free of any other virus genotype. In the second method, linear baculovirus DNA produced by digestion with a restriction endonuclease is mixed with the transfer vector and used to infect insect cells (Kitts and Possee, 1993). The transfer vector contains sequences from the virus genome that span the break in the DNA; these sequences flank the foreign gene to be inserted into the baculovirus genome. When the linear virus DNA and transfer vector enter the insect cells, recombination between the homologous sequences in both molecules effects transfer of the foreign gene into the baculovirus genome. Unfortunately, the recombinant virus recovered from the infected cells is usually contaminated with a low level (ca. 5%) of parental virus. This has to be removed by titrating the virus mixture (parental and recombinant) using a plaque assay in monolayers of insect cells to derive clonal stocks of the recombinant virus. A single operator, using either method, cannot easily make more than 25 recombinant viruses per week.

Neither of the methods described above is readily amenable to the high throughput generation of recombinant viruses; both require too many manipulations of plasmids, viruses and cells (see Table 1). Such a method is now in demand because of the rapid deposition of sequence data from the human genome project (and other species, such as the mouse) in the databases world-wide. To interpret such vast stores of information, it will be necessary to express thousands of genes in alternative hosts (e.g. insect cells) to derive sufficient material to determine protein function.

The inventors proposed that to develop an improved system for making recombinant baculoviruses would require the use of a defective form of the virus genome that could not, on its own, initiate replication after transfection into insect cells. However, when mixed with a plasmid transfer vector containing a foreign gene and a sequence capable of restoring replication gene, recombination between the two molecules would regenerate replication-competent virus.

This procedure was demonstrated in three experiments. In the first, lef-2 was deleted from the AcMNPV genome using a yeast system to manipulate the virus DNA. In the second, 6385 bp, containing ORF1629, protein kinase 1 and lef-1, was deleted from the AcMNPV genome which was maintained in bacterial cells. In the third, only a small part of ORF1629 was deleted from the virus genome maintained in bacteria. Defective AcMNPV genomes, maintained in yeast or bacterial cells, could be purified, mixed with a suitable rescue plasmid and used to transfect insect cells to recover infectious virus.

The inventors have inactivated the ORF1629 using bacterial cells as an intermediary host to maintain the AcMNPV genome.

This demonstrates that it is possible to generate and maintain replication deficient baculovirus in intermediary hosts. The virus can be rescued using a suitable rescue vector encoding a nucleic acid sequence to correct the deficiency. This has enabled a new method for cloning foreign genes in baculovirus to be identified.

The invention provides a method for cloning, and optionally expressing, a gene comprising the steps of:

- (i) providing a replication deficient baculovirus vector;
- (ii) providing a rescue vector encoding:
 - (a) a nucleic acid sequence which is capable of restoring replication in the replication-deficient baculovirus vector; and
 - (b) at least one gene to be cloned;

- (iii) causing the replication-deficient baculovirus vector and rescue vector to recombine to produce a replication-enabled baculovirus vector comprising at least one gene to be cloned; and
- (iv) growing the replication-enabled baculovirus vector within a suitable invertebrate cell.

Preferably the invertebrate cell is an insect cell, but other suitable invertebrate cells in which baculovirus may grow may be used.

By replication-deficient baculovirus vector we mean a DNA molecule based upon the genome of a baculovirus, but which has had at least one gene necessary for replication either deleted or mutated so that the baculovirus vector can no longer replicate on its own. For example, one or more functional genes such as *lefs 1-12*, *dnapol*, *p143*, *p35*, *ie-1*, *ie-2*, *p47*, *ORF1629*, and *pp31* may have been deleted or mutated to inactivate them. These genes are known to be involved in baculovirus replication (Kool, *et al.* 1994; 1995; Lu *et al.* (1997); Lu and Miller 1995; Rapp, *et al.* 1998; Fan, *et al.* 1996; 1998; Todd, *et al.* 1995; 1996; McLachlin and Miller 1994; Guarino 1998).

The ability to replicate may be restored by recombination with a rescue vector comprising one of the functional genes, or a functional fragment or functional mutation thereof.

Preferably the baculovirus vector is based upon the genome of AcMNPV.

By gene we mean a nucleic acid sequence which is capable of being transcribed into a protein or peptide of interest. The gene to be cloned is preferably operably linked to regulatory elements necessary for expression of said gene within the invertebrate cell. Operatively linked refers to the juxta position such that the normal function of the components can be performed. Control sequences refers to DNA sequences necessary for the expression of an operatively linked gene in a particular host organism. Control sequences refers to DNA sequences which are suitable for eukaryotic cells, for example, are promoters, polyadenylation signals and enhancers. Preferably the control sequences

Preferably the gene is under the control of a promoter selected from a baculovirus polyhedrin promoter and a baculovirus p10 promoter.

Preferably, the replication-deficient baculovirus vector comprises one or more replication elements to enable replication within one intermediate host. For example, if the intermediate host is a bacterial cell, then the vector may comprise a bacterial origin of replication, *ori*. If the intermediate host is a yeast, then the vector may comprise an autonomous replication sequence, such as ARS1 and a centromere functional sequence, such a CEN1. Such replication elements are well known in the art. The intermediate host may be *Escherichia coli* or *Saccharomyces cerevisiae*.

The replication-deficient baculovirus vector may also comprise one or more selection genes to enable host cells comprising the replication-deficient baculovirus vector to be selected. Such selection gene may be antibiotic-resistance genes or nutritional. For example, antibiotic-resistance genes such as ampicillin, tetracycline, chloramphenicol, kanamycin or neomycin may be used in bacteria. The host cell will be selected according to the selection gene used in the vector. Therefore, a bacterial cell comprising a replication-deficient baculovirus vector containing a chloramphenicol resistance gene may be selected for by growing the cells in the presence of chloramphenicol. In yeast cells, nutritional genes such as URA3, *Trp* and *His* may be used. For example, if URA3 is used as a selection gene, then the host cell will be one that cannot grow in the absence of Uracil unless the baculovirus containing URA3 is present. Cells containing the vector can then be selected by growing the yeast cells in the absence of Uracil.

The rescue vector may similarly contain replication elements to enable it to be replicated within a desired host, together with selection markers to enable cells containing the rescue vector to be identified.

The rescue vector preferably contains one or more sites into which a gene to be cloned may be inserted. Methods for inserting foreign genes into vectors are well known in the art. For example, the vector may comprise a unique restriction endonuclease site into which the gene of interest may be inserted; preferably either side of the site are suitable promoter and termination sequences.

Rescue vectors which can insert multiple foreign gene coding sequences can be produced using techniques known in the art. For example, it is possible to construct a rescue vector comprising a polyhedrin gene promoter and transcription termination sequence upstream of, and in the opposite orientation to, a second polyhedrin gene promoter. It is also possible to insert a small DNA fragment encompassing the p10 promoter upstream, but in the opposite orientation of a polyhedrin promoter. The construction of multiple expression vectors is discussed in detail in the book by King and Possee (*Supra*).

The replication-deficient baculovirus vector and/or rescue vector may be inserted into a suitable intermediate host by techniques known in the art. For bacterial cells, electroporation or calcium chloride mediated uptake of DNA may be used (Sambrook *et al.*, 1989). For yeast cells methods such as treatment with lithium acetate may be used (Ito *et al.*, 1983).

The replication-deficient baculovirus vector and rescue vector may be recombined either within the intermediate host or most preferably within the invertebrate cell.

Typically, the replication-deficient baculovirus vector and the rescue vector are purified and isolated from any host in which they reside since purification techniques are well known in the art. For example, a total DNA preparation may be undertaken followed by sucrose or caesium chloride density gradient purification. Each of the vectors are inserted

09807809 60820860

into a suitable invertebrate cell by known techniques, for example as shown in King and Possee (1992). The two vectors then undergo recombination within the cell to produce a replication enabled baculovirus vector comprising at least one gene to be cloned. Such recombinant baculoviruses are selected for since they are able to undergo replication and thus infect further cells and multiply.

Preferably the replication-deficient baculovirus lacks a gene coding for polyhedrin. This has the advantage that contaminating polyhedrin is not produced.

The invention also relates to a replication-deficient baculovirus vector for use in a method of the invention. Preferably such a vector comprises one or more nucleic acid sequences, which enable the vector to replicate within an intermediate host. Such sequences are described above.

A further aspect in the invention provides a rescue vector for use in a method according to the invention. Preferably the rescue vector is constructed as described above.

A still further aspect of the invention provided a kit for use in the method of the invention comprising a replication-deficient vector of the invention and/or a rescue vector according to the invention. The kit may additionally comprise one or more buffers, preservatives or stabilising agents to enable the vectors (s) to be stored or transported with minimal degradation of the vector. Such buffers, preservatives and stabilising agents are well known in the art.

Oligonucleotides used to construct recombinant viruses according to the invention are also provided.

The invention will now be described by way of example only, with reference to the following figures.

Figure 1. Genomic organisation of parental and recombinant baculoviruses with modified polyhedrin and *lef-2*. (a) AcMNPV. Relative positions of *lef-2*, ORF603 and polyhedrin.

09807809 073004

(b) AcAUC. The insertion of the ARS-URA3-CEN4 cassette (not drawn to scale) relative to a deletion in polyhedrin. (c) Δ *lef-2.sup4-o*. The *sup4-o* was inserted into *lef-2* via homologous recombination in yeast cells harbouring AcAUC. Selected restriction enzyme sites are shown with appropriate genomic co-ordinates (Ayres *et al.*, 1994).

Figure 2. Genomic organisation of viruses with C-MYC added to LEF-2. (a) *Aclef-2.c-myc5'*. The c-myc coding region was inserted at the 5' end of *lef-2*. The C-MYC sequence is shown as bold text above the coding region. The additional amino acids introduced between C-MYC and LEF-2 via the XbaI site are italicised. (b) *Aclef-2.c-myc3'*. The c-myc coding region was inserted at the 3' end of *lef-2*. The positions of oligonucleotide primers used to generate selected DNA fragments in the *lef-2* region for construction of the modified gene are indicated above and below the central genomic map.

Figure 3. Temporal expression of *lef-2* transcript.

(A) mRNA were extracted from Sf-21 cells either mock-infected (Mi), infected with *Acc-myclef-2* or AcMNPV C6 at a m.o.i. of 20, at the times (hours post infection) indicated above the lanes. mRNA (100 ng) were subjected to RT-PCR using two internal specific primers of *lef-2*. The size of the specific RT-PCR product is indicated on the right. The W lane corresponds to the "smartladder SF" size marker from Eurogentec (1000, 800, 700, 600, 500, 400, 300, 200 and 100 bp from the top to the bottom).

(B) mRNAs were extracted from Sf-21 cells either mock infected (Mi) or infected with AcMNPV-C6 or *Acc-myclef-2* at a m.o.i. of 20, at times (hours post infection) indicated above the lanes and subjected (2 µg per lane) to Northern blot. The sizes of the markers are shown on the left of the blot and the location of the major band hybridising with the *lef-2* probe is indicated by an arrow on the right.

Figure 4. 5' mapping of the *lef-2* transcripts.

Total RNA from mock infected or *Acc-myclef-2*-infected cells were extracted at different times post infection and incubated with primer *lef-2* PE4 (A) or *lef-2* PE3 (B) depending on the promoter mapped (early or late). The reaction products were separated on a 6% sequencing gel, in parallel with a sequencing ladder generated with the same primer.

Products are indicated on the right by arrows. Sequence and initiation sites are shown on the left. 12a: treatment with aphidicolin. 12c: treatment with cycloheximide.

Figure 5. Expression of LEF-4, GP-64 and CHI in *Acc-myclef-2* and AcMNPV C6-infected *Sf-21* cells.

Western blot analysis of steady-state levels of selected early (LEF-4 and GP-64) and late (GP-64 and chitinase) proteins in *Acc-myclef-2* and wt-infected *Sf-21* cells from 4 to 24 hr p.i. The protein bands are indicated by arrows. The numbers above each lane indicate time post infection and the proteins analysed is indicated on the left.

Figure 6. Western blot analysis of tagged-*lef-2* product in *Acc-myclef-2* or AcMNPV C6-infected *Sf-21* cells.

Western blot analysis of the tagged-*lef-2* product in *Acc-myclef-2* or AcMNPV-C6-infected *Sf-21* cells from 4 to 24 hr p.i. C-MYCLEFT-2 protein was identified using the monoclonal anti-C-MYC antibody (clone9E10) and detected with a chemoluminescent substrate. The corresponding times post infection (hr p.i.) are indicated above the lanes (Mi, mock infected). Size standards are indicated on the left and immunoreactive proteins are shown by arrows.

Figure 7. Sub cellular localisation of C-MYCLEFT-2 by indirect immunofluorescence.

Sf-21 cells were mock-infected or infected with *Accmyclef-2* and stained both with anti-C-MYC antibody (clone9E10) and anti-mouse conjugated to TRITC. A) Background fluorescence on uninfected cells. B) Cells stained at 9 hr p.i. C) Cells stained at 24 hr p.i. Laser levels were equivalent between all panels.

Figure 8. Genomic organisation of parental and recombinant baculoviruses with modified ORF1629. (a) Genetic organisation of AcMNPV showing positions of *Bgl*II and *Arv*II restriction enzyme sites. The positions and orientation of the polyhedrin and ORF1629 genes are indicated; not drawn to scale. (b) Genomic organisation of AL1*Arv*II showing position of second *Arv*II site added to the virus genome. The polyhedrin gene in this virus is non-functional as it lacks the first 150 nucleotides of the coding region and cannot make a mature protein.

MATERIALS and METHODS

Insect cells and viruses

Spodoptera frugiperda IPLB-Sf21 cells were propagated at 28°C in TC100 medium supplemented with 10% (v/v) foetal calf serum (FCS). AcMNPV C6 and other recombinant viruses were amplified and titrated according to standard protocols (King and Possee, 1992). AcMNPV DNA replication was blocked by treating the virus-infected cells with aphidicolin (5 µg/ml; Sigma, USA) while protein synthesis was inhibited by using cycloheximide (200 µg/ml; Sigma, USA) according to a recent modification (Ross and Guarino, 1997).

YEAST BASED SYSTEM

Yeast cells and transformation

The *Saccharomyces cerevisiae* strain used in this study was y657 (*mata his3-11, 15 trp1-1 ade2-1 leu2-3, 112 ura3-52 can1-100 his4:HIS3*; Newman and Norman, 1991) kindly provided by G. Patel, ICRF, London, UK. This was grown in rich medium (yeast extract, peptone, dextrose [YPD]) at 30°C. Yeast strains maintaining the baculovirus genome were grown in minimal medium supplemented with adenine (20 µg/ml), histidine (20 µg/ml), leucine (60 µg/ml), tryptophan (20 µg/ml) and casamino acids (10mg/ml) (Sherman, 1991). Canavanine resistant colonies were selected on minimal medium plates containing 60 µg/ml canavanine sulphate (Sigma, UK).

Transformation of yeast with the AcMNPV genome and other plasmids was carried out with the lithium acetate method (Ito *et al.*, 1983) using high molecular weight DNA as a carrier (Schiestl and Gietz, 1989). Briefly, y657 cells were grown in 5ml YPD medium to saturation. This culture was used to inoculate 250ml YPD medium, supplemented with 30 µg/ml adenine hemisulphate and the cells grown overnight at 30°C to a cell density corresponding to OD₆₀₀ = 0.3 to 0.5. The cells were harvested by centrifugation (4000g; 5 min) and washed with 10ml sterile water. The cells were then resuspended in 1.5ml freshly prepared lithium solution (10mM Tris-HCl, pH7.5/1mM EDTA/0.1M lithium acetate,

pH7.5). To transform the yeast cells, 200 µg carrier DNA (salmon sperm DNA boiled 3', then snap-chilled) was mixed with 5 µg transforming DNA in a volume of less than 20 µl. The yeast suspension (200 µl) was added to the DNA along with 1.2ml freshly prepared PEG solution (40% PEG 3350/ 10mM Tris-HCl, pH7.5/ 1mM EDTA/ 0.1M lithium acetate, pH7.5). The mixture was shaken at 30°C for 30 minutes, then heat-shocked at 42°C for exactly 15 minutes. The cells were pelleted and resuspended in 1ml TE buffer (10mM Tris-HCl, pH7.5/ 1mM EDTA). Aliquots (200 µl) were spread onto minimal media plates and incubated at 30°C for 3-4 days.

Plasmid and recombinant virus constructions

The plasmid pAcAUC, containing the *ARS* (A), *URA3* (U) and *CEN* (C) sequences at the *polh* locus (Patel *et al.*, 1992) was mixed with *Bsu36I*-linearised BacPAK5 DNA (Kitts and Possee, 1993), in the presence of lipofection and used to transfect Sf21 cells (King and Possee, 1992). Progeny virus was plaque purified and amplified to produce polyhedrin-negative stocks (AcAUC) containing the yeast AUC elements. Infectious virus DNA was purified and used to transform y657 cells to yield yAcAUC.

The vector pUC8/6/8 (Possee, 1986), containing the AcMNPV *EcoRI*-I region was used to generate a plasmid containing a modified *lef-2* and the *sup4-o* yeast selectable marker. An octanucleotide *Bgl*III linker was inserted at the *EcoRV* site upstream of *polh* to create pUC8/6/8-*Bgl*III. This plasmid was digested with *Hind*III, recircularised and amplified in bacteria, then digested with *Sal*I (Fig. 1). The ends of the linear DNA were repaired with the Klenow fragment of DNA polymerase and ligated with a blunt-ended DNA fragment containing *sup4-o* to produce *plef2Δ.sup4-o*. (The *sup4-o* was originally obtained from G. Patel and inserted into the *EcoRI* site of pUC118 to provide a convenient supply). Lithium acetate-treated yAcAUC yeast cells were transformed with *plef2Δ.sup4-o* and grown on minimal medium plates lacking uracil and adenine. Small white colonies were replica plated on the same medium in the presence or absence of canavanine sulphate. Canavanine sensitivity indicated that *sup4-o* was inserted into the virus genome maintained within the yeast cell.

Table 2

Sequences of synthetic oligonucleotides.

Oligo	Sequence ^a	Strand ^b	REN site ^c	Position
<i>c-myc1</i>	GATCCATAATGGAGCAAAAGCTCATTCTGAA GAGGACTTGAATTCTAGATAACTGCA	+	<i>XbaI</i>	N/A
<i>c-myc2</i>	GTTATCTAGAATTCAAGTCCTCTTCAGAAATGA GCTTTTGCTCCATTATG-	-	<i>XbaI</i>	N/A
CLH1	CGGCAGATCTATAATGGCGAATGCA	+	<i>BglIII</i>	3089-3100
CLH2	GCCAGGATCCATAATTACAAATAGGATTGAG	-	<i>BamHI</i>	3698-3718
CLH3	CGGCTCTAGAATGGCGAATGCATC	+	<i>XbaI</i>	3089-3102
CLH4	GCCGCTGCAGTCAATAATTACAAATAGG	-	<i>PstI</i>	3704-3721
CLH5	GGCCGGTACCGAGTTCGTTGACGC	+	<i>KpnI</i>	2334-2347
CLH6	CGCGAGATCTACTTCGCGGCTTCTCGCACC	-	<i>BglIII</i>	3069-3088
CLH7	GGCCCTGCAGATAATAAAACAATTATAAAT	+	<i>PstI</i>	3722-3741
CLH8	CGCGAAGCTTAGCAACTATATATT	-	<i>HindIII</i>	4411-4424
<i>Lef-2PE3</i>	AAGCTCGTGCCGGAACGCGTGACAGATCG	-		2886-2915
<i>Lef-2PE4</i>	TGTAGTCGGCAGTTCATTTGGGCGTGATCG	-		2966-2995
<i>Lef-2RT1</i>	AAGAAAACAATGTACCGCGCGGCGG	+		3438-3462
<i>Lef-2stop</i>	ATGCGAATTCTCAATAATTACAAATAGGATTG	-	<i>EcoRI</i>	3700-3721

^a The first first nucleotide corresponding to AcMNPV sequence is shown^b Relative to the coding strand of *lef-2*.^c The restriction enzyme site is underlined in the sequence of the oligonucleotide.

TABLE 2 " SEQ ID NO: 10

To construct transfer vectors containing a c-myc epitope tag at either end of *lef-2*, oligonucleotides *c-myc1* and *c-myc2* were constructed (Table 2). These specified the sense and anti-sense *c-myc* sequences respectively. The oligonucleotides were annealed to create the double stranded *c-myc* coding region with *Bam*HI and *Pst*I cohesive ends. The epitope coding region also included an *Xba*I site directly upstream of the stop codon. The annealed oligonucleotides were inserted into a modified pUC118 plasmid (containing a *Bgl*III site directly upstream of the *Bam*HI site) between the *Bam*HI and *Pst*I sites to derive pUC.*c-myc*. Copies of the *lef-2* coding region were created using PCR. These possessed either 5'-*Bam*HI and 3'-*Bgl*III ends and no TGA stop codon, or 5'-*Xba*I and 3'-*Pst*I ends including the TGA stop codon. These were inserted into pUC.*c-myc* separately at the *Bam*HI or the *Xba*I and *Pst*I sites respectively to derive two plasmids in which the *c-myc* epitope was either upstream or downstream of *lef-2*. PCR was then used to derive upstream and downstream regions of *lef-2* possessing 5'-*Kpn*I, 3'-*Bgl*III or 5'-*Pst*I, 3'-*Hind*III ends respectively. These were inserted at either end of the *c-myc*-tagged *lef-2* in both plasmids to derive pA*clef-2.c-myc*5' and pA*clef-2.c-myc*3' (Fig. 2).

Yeast DNA extraction and transfection of insect cells

Total yeast DNA was prepared as described (Patel *et al.*, 1992) and layered onto a 5-20% continuous sucrose gradient in STE (200mM NaCl/ 10mM Tris pH7.5/ 1mM EDTA). The gradient was centrifuged at 35,000 rpm for 3 hours at 20°C in a Beckman SW41 rotor. The gradient was then harvested in 0.5ml fractions by downward displacement. The DNA in each fraction was ethanol precipitated, pelleted and resuspended in 50 µl TE pH 7.5. Aliquots (10 µl) of each DNA fraction were placed in sterile polystyrene bijoux bottles with 0.5ml TC100 lacking FCS; on occasion, 500 ng of a rescuing plasmid (pUC8/6/8) was included. An additional 0.5ml TC100 minus FCS containing 5 µl lipofectin was added to each DNA solution and the mixtures were incubated at room temperature for 15 to 30 minutes. Thereafter, 3 x 10⁵ Sf21 cells in 35mm cell culture dishes were transfected as described by King and Possee (1992). The dishes were incubated at 28°C for 6 days and monitored daily for signs of viral infection. The virus-containing medium was then harvested and titrated in a plaque assay.

Western blot and immunofluorescence analysis

Monolayers of 10^7 Sf21 cells were infected with AcMNPVC6 or *Aclef-2.c-myc5'* at a multiplicity of infection (m.o.i.) of 20 or mock-infected with medium. Cells were harvested at various times, pelleted, washed twice with PBS and lysed in dissociation mixture (Laemmli, 1970). Protein samples (equivalent of 3×10^6 cells) were then loaded and separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were incubated overnight in Tris-NaCl buffer (TBS: 137mM NaCl; 20mM Tris-HCl, pH 7.6) containing 10% dried milk and 0.1% Tween-20. C-MYC monoclonal (clone 9E10), GP64-EFP monoclonal (AcV5), LEF-4 polyclonal and CHI [AcMNPV chitinase] polyclonal antisera have been described previously (Evan *et al.*, 1985; Blissard and Rohrmann, 1989; Durantel *et al.*, 1998a; b; Hawtin *et al.*, 1995, respectively).

Western blots were performed with appropriate dilutions of polyclonal or monoclonal antibodies. Immunoreactive proteins were detected using the appropriate secondary antibody linked to the peroxidase (Sigma, USA) followed by incubation with a chemoluminescent substrate (Amersham, UK), according to the manufacturer's instructions.

Immunofluorescence staining was performed as described previously (Durantel *et al.*, 1998b) with an important modification. First and secondary antibodies were applied twice in order to amplify the staining. The preparations were examined under a Zeiss LSM410 confocal laser scanning microscope.

RNA procedures

Messenger RNA isolation, Northern blot, primer extension, RT-PCR and 3'RACE (rapid amplification of cDNA ends) were described previously (Durantel *et al.*, 1998a; b). Extraction of total RNA was performed using the RNeasy midi kit following the manufacturer's instructions (Qiagen, USA). The synthetic oligonucleotides used in primer extension were lef-2PE3 and lef-2PE4; in RT-PCR, lef-2RT-1 and lef-2stop; in RT-PCR, lef-2RT1 and oligo(dt). The sequence of each primer is listed in Table 1, with further information on its position relative to the AcMNPV genome.

BACTERIAL BASED SYSTEM

Bacterial cells and plasmid purification

Escherichia coli DH5 α F' were made competent for transformation with plasmid DNA by treating logarithmic phase cells with calcium chloride (King and Possee, 1992). The *E. coli* DH10B cells were made competent for electroporation as described by Sambrook *et al.* (1989). Plasmids were purified from bacterial cultures using Qiagen gravity flow columns (Qiagen Ltd., Crawley, UK) or caesium chloride gradients (King and Possee, 1992). Baculovirus DNA was isolated from bacterial cells using a modified method and buffers recommended for the purification of plasmid DNA from *E. coli* by Qiagen. Briefly, bacterial cells grown to stationary phase after overnight incubation at 37°C were pelleted, resuspended in 300 μ l P1 buffer and treated with ribonuclease A (100 μ g/ml) before lysis with an equal volume of P2 buffer. After 5 min incubation at room temperature, 300 μ l P3 buffer was added to the lysate and left on ice for 15 min. Thereafter, cellular debris was pelleted and the supernatant fraction, containing baculovirus DNA, precipitated with 0.7 vol propanol. The DNA was pelleted, washed twice with 75% ethanol, briefly dried and resuspended in 40 μ l TE buffer (10 mM Tris-HCl, pH 7.8; 0.1 mM EDTA).

Plasmid construction and recombinant virus preparation

Acpi0Bac. The plasmid transfer vector pAcUW1 (Weyer *et al.*, 1990) was digested with *Hind*III and then treated with calf intestinal phosphatase (CIP) according to Sambrook *et al.* (1989). The plasmid pBace3.6 was digested with *Hind*III to remove the bacterial origin of replication and chloramphenicol resistance gene. The fragment containing these elements (6380 bp) was isolated by fractionating the digested plasmid using an agarose gel, excising the appropriate DNA band and removing the agarose with a Qiagen spin column. The concentration of the DNA fragment was assessed by analysis on an agarose gel. It was then ligated with the *Hind*III-digested, CIP-treated pAcUW1 and used to transform *E. coli* DH5 α F' to derive pAcUW1.Bac, which was amplified and purified according to standard protocols. The plasmid (0.5 μ g) was then mixed with *Bsu*36I-digested AcUW1.lacZ virus genomic DNA (0.1 μ g) and used to transfect Sf21 cells in the presence of lipofectin (King and Possee, 1992). The virus progeny was titrated in a plaque assay using Sf21 cells. The

plaques were stained with X-gal at 4 days p.i. and those failing to exhibit a blue colour the next day were isolated and the virus amplified in Sf21 cells. This was designated Acp10Bac. Virus DNA was prepared from purified virus particles according to standard procedures (King and Possee, 1992) and used to transform *E. coli* DH10B cells via electroporation.

BacPAK6p10Bac. Virus DNA isolated from Acp10Bac was mixed with pBacPAK6 (Kitts and Possee, 1993) and used to cotransfect Sf21 cells. The virus progeny was titrated in a plaque assay using Sf21 cells and at 4 days p.i., plaques staining blue in the presence of X-gal and lacking polyhedra were isolated (BacPAK6p10Bac). The recombinant viruses were amplified in Sf21 cell and virus DNA purified as before.

AL1AvrII. The plasmid transfer vector pAcAL1 was digested with *Swa*I and *Sna*BI, then subsequently treated with CIP. This modified plasmid was then ligated with two pairs of synthetic oligonucleotides (*Swa*I F and R; *Avr*II F and R – see Table 3), phosphorylated at their 5' ends. The ligation mixes were used to transform *E. coli* DH5 α F', which were subsequently plated onto agar plates containing ampicillin. Bacterial colonies were amplified in liquid medium and plasmid DNA purified. This was digested with *Swa*I and *Sna*BI to confirm that the synthetic oligonucleotides had been inserted in the correct orientation. Plasmids with the oligonucleotides in the correct orientation were designated pAcAL1*Swa*IF/R.*Avr*II F/R. The modified regions of these plasmids were subsequently sequenced to confirm that the oligonucleotides had been synthesised correctly. pAcAL1*Swa*IF/R.*Avr*II F/R was then digested with *Sna*BI and *Avr*II, treated with CIP and ligated with another pair of synthetic oligonucleotides (*Sna*BIF and R – see Table 3). The ligation mixture was used to transform *E. coli* DH5 α F' as described above. The ampicillin-resistant colonies were amplified, plasmid DNA prepared and sequenced across the modified region to confirm the insertion of the predicted oligonucleotides. Plasmids with the correct sequences were designated pAcAL1*Avr*II, to denote addition of the synthetic *Avr*II site within the 3' end of the ORF1629. One such plasmid was mixed with Bsu36I-digested BacPAK6p10Bac and used to cotransfect Sf21 cells to derive AL1*Avr*II after plaque purification of the virus progeny. This virus was amplified further in Sf21 cells and genomic DNA purified as before.

AcORF1629. BacPAK6p10Bac genomic DNA was digested with *Bsu*36I and then treated with the large sub-unit of the *E. coli* DNA polymerase 1 (Klenow) in the presence of dATP, dGTP, dCTP and TTP (Sambrook *et al.*, 1989) to repair the ends of the DNA molecules. The reaction mixture was heated to 60°C for 20 min, prior to subsequent storage at 4°C. A sample of the virus DNA was then ligated to recircularise the genome, before electroporation of DH10B cells and selection on agar plates. Chloramphenicol-resistant colonies were amplified in liquid cultures and virus DNA purified.

Table3: Synthetic oligonucleotides used to construct recombinant viruses

Oligo	Sequence (5' – 3')
SwalF	AAATTCAGATATAAAGACGCTGAAAATCATTG
SwalR	TGATTTTCAGCGTCTTTATATCTGAATT
AvrIIF	ATTTTCGCTCTAACATACCACCCTAGGGATGTAC
AvrIIR	GTACATCCCTAGGGTGGTATGTTAGAGCGAAAATCAAA
SnaBIF	CTAGGGATTATAAATTTAATGAATTATTAATAATAC
SnaBIR	GTATTTTAATAATTCATTAAATTTATAATCC

RESULTS

Production of a recombinant baculovirus DNA containing a deletion within the *lef-2* gene using yeast cells as intermediate host.

A recombinant virus (AcAUC), containing the *ARS*, *CEN* and *URA3* sequences at the *polh* locus, was produced to enable propagation of viral DNA in yeast cells. The genetic organisation of this virus is shown in Figure 1. The correct insertion of the three yeast elements in the *AcMNPV* genome was confirmed by Southern hybridisation analysis (data not shown).

Virus DNA was extracted from purified AcAUC budded virus particles and used to transform the yeast strain y657. Yeast cells containing the AcAUC DNA were selected on dropout plates lacking uracil. Yeast cells were transformed at an efficiency of approximately 2×10^5 colonies per μg transforming DNA. Total DNA was extracted from amplified yeast cultures (yAcAUC), fractionated on sucrose gradients and used to transfect *S. frugiperda* cells. After six days, it was determined that the transfected cell culture medium contained 5×10^4 pfu/ml. Cell cultures transfected with 100 ng AcMNPV DNA produced 9.7×10^5 pfu/ml over the same period. Subsequent amplification of AcAUC derived from yeast in insect cells produced virus stocks of normal titre ($> 10^7$ pfu/ml).

In order to delete *lef-2* from AcAUC DNA maintained in yAcAUC, we produced a transfer vector (*plef-2.sup4-o*) containing *sup4-o* in lieu of *lef-2* (Fig. 1c). Yeast strains with ochre mutations in both *ade2* and *can1* grow as pink colonies in the absence of adenine and are insensitive to canavanine. Suppression of these mutations by *sup4-o* causes the production of white colonies that are sensitive to canavanine. The yAcAUC cells were transformed with *plef-2.sup4-o* and colonies containing *sup4-o* were selected by growth on dropout plates lacking uracil and adenine. Adenine independent colonies (white) were then replica-plated onto dropout plates lacking uracil but containing canavanine sulphate. Colonies sensitive to canavanine were retro-selected. Twelve yeast colonies were isolated with the correct phenotype of *ura3+* and *sup4-o+* by replica plating and amplified in liquid culture.

Transfection of insect cells with viral DNA isolated from *ura3+*, *sup4-o+* yeast colonies.

Virus DNA was isolated from twelve yeast clones identified as *ura3+* and *sup4-o+*. Each sample was used to transfect *S. frugiperda* cells in the presence or absence of pUC8/6/8, a plasmid containing an intact *lef-2* (Possee *et al.*, 1991). The addition of this plasmid to the transfection mix was predicted to rescue the expected deletion in *lef-2*, via homologous recombination in insect cells, and permit virus replication. Nine out of the twelve DNA preparations caused infection of the *S. frugiperda* cells irrespective of the presence of the rescuing plasmid (data not shown). When each of the other three DNA preparations

Table 4

Transfection of *Sf21* cells with virus DNA

Viral DNA	pUC8/6/8	Titre after transfection (p.f.u./ml) ^a	Titre after progeny virus amplification (p.f.u./ml) ^b
AcMNPV (100ng)	-	2×10^6	5×10^7
yAc Δ lef-2.sup4-o ⁹	-	ND	ND
yAc Δ lef-2.sup4-o ⁹	+	9×10^3	5×10^7
yAc Δ lef-2.sup4-o ¹⁰	-	ND	ND
yAc Δ lef-2.sup4-o ¹⁰	+	5×10^4	5×10^7
yAc Δ lef-2.sup4-o ²¹	-	ND	ND
yAc Δ lef-2.sup4-o ²¹	-	6×10^4	5×10^7

^a Progeny virus was titrated 6 days after transfection of *Sf21* cells.^b Infectivity of virus stocks after amplification in *Sf21* cells.

T00E20" 60820860

(AcΔ.*lef-2.sup4-o*⁹, ¹² or ²¹) were used to transfect Sf21 cells without pUC8/6/8, productive infection of the cells was not observed. However, co-transfection of insect cells with each of these DNA preparations and the rescuing plasmid resulted in low levels of infectious budded virus production (Table 4). In comparison with insect cells transfected with 100 ng AcMNPV DNA, 33 - 200-fold less virus was produced. When these primary virus stocks were amplified in suspension cultures of insect cells, however, normal virus titres were attained for all samples (Table 4).

Production of a c-myc-tagged AcMNPV *lef-2*

The AcΔ.*lef-2.sup4-o*⁹ was used to derive a recombinant virus with a human C-MYC coding region added to that of *lef-2*, to permit the identification of LEF-2 in virus-infected cells. The C-MYC epitope or tag comprises 12 amino acids (NH₂-MEQKLIIEDLNSR-COOH), which can be recognised by a monoclonal antibody (9E10; Evan *et al.*, 1986). It was not known whether addition of this epitope would affect the folding and/or the activity of LEF-2 when added to either end of the protein. Two transfer vectors were constructed containing the *c-myc* coding sequence at either the 5' (p*Aclef-2.c-myc5'*) or 3' (p*Aclef-2.c-myc3'*) ends of the *lef-2* coding region (Fig. 2). These were used individually to co-transfect insect cells with AcΔ.*lef-2.sup4-o*⁹ DNA isolated from yeast cells. After 6 days, the cell culture medium for each sample was titrated in a plaque assay to monitor virus production. Infectious virus (*Aclef-2.5'c-myc*) was only produced by cells co-transfected with AcΔ.*lef-2.sup4-o*⁹ and p*Aclef-2.c-myc5'*. This was amplified further in insect cells to derive a virus stock (*Aclef-2.c-myc5'*) of comparable titre to that produced by AcMNPV (ca. 1-2 x 10⁸ p.f.u./ml)

To confirm that the *c-myc* coding region was present at the 5' end of *lef-2* in *Aclef-2.c-myc5'*, total DNA was extracted from virus-infected cells and the *lef-2* region amplified by PCR. The resulting DNA fragment was digested with *Bam*HI to detect the extra site inserted at the start of *lef-2* when *c-myc* was present. All three viruses exhibited the presence of *c-myc* at the 5'-end of *lef-2* (data not shown).

Analysis of *lef-2* transcription

The production of *Aclef-2.c-myc5'* virus stocks of normal infectivity suggested that transcription of *lef-2* was not affected by the addition of the *c-myc* sequences. This was confirmed by analysing the temporal regulation of *lef-2* using RT-PCR to amplify purified mRNA extracted from AcMNPV-, *Aclef-2.c-myc5'*- or mock-infected cells. Two oligonucleotide primers (*lef-2*RT1 and *lef-2*stop) internal to *lef-2* were used to amplify a 283-bp fragment. For both virus infections, *lef-2*-specific mRNA sequences were amplified as early as 1 hr p.i., with yields increasing until 12 h p.i. The transcripts remained stable until at least 48 hr p.i. (Fig. 3A). The *lef-2* transcripts were also analysed at selected times post infection using Northern blot hybridisation with a strand-specific riboprobe. Figure 3B shows a typical result obtained with AcMNPV. A major transcript with a size of 1 kb appeared weakly at 5 hr p.i. and accumulated to a higher level up to 24 hr p.i. Other products including a band between 1.5 and 1.6 kb were detected both at early and late times after infection (Fig. 3B). Similar results were obtained with *Aclef-2.c-myc5'*.

The transcription start sites for *lef-2* in AcMNPV-infected cells were determined by primer extension using two different oligonucleotides. Primer *lef-2*PE4 was used to detect the early start site. An extension product was obtained with mRNA extracted at 6 and 12 hr p.i., corresponding to a start site located 279 bp upstream from the *lef-2* ATG codon. This mapped at a C within the sequence CAATGCGCCCGTTGT (Fig. 4A). When virus-infected cells were treated with cycloheximide, no products were obtained in the subsequent primer extension analysis, underlying the early character of this promoter. Primer *lef-2*PE3 was used to detect the late start site. One major extension product was obtained with mRNA extracted at 12 and 24 hr p.i. (Fig. 4B). This mapped the transcription start site at an adenine within a TAAG motif located 361 bp upstream of the ATG. When mRNA was extracted from virus-infected cells treated with aphidicolin, no primer extension products were obtained. Identical results were obtained with mRNA from *Aclef-2.c-myc5'*-infected cells (data not shown).

The 3' end of the *lef-2* transcript was determined by sequencing DNA fragments generated by RACE-PCR after RT amplification of mRNA purified at 9 hr p.i. from AcMNPV- or *Aclef-2.c-myc5'*-infected cells. A single product with a length of approximately 330 bp was obtained from both samples (data not shown). Using the *lef-2* RT1 primer, this fragment was sequenced to determine the precise point of addition of the poly(A) tail. This mapped at a A residue located 17 bp and 9 bp downstream from the stop codon of *lef-2* and a AATAAA motif respectively. Combining the data from primer extension and 3' end mapping predicts an early *lef-2* specific transcript of 928 bases and a late transcript of 1000 bases in AcMNPV-infected cells.

Expression of LEF-4, GP-64 and CHI in *Aclef-2.c-myc5'* -infected cells

To confirm that synthesis of a modified form of LEF-2 did not affect expression of other virus genes, the production of three other virus proteins was examined. These included an early gene (*lef-4*), a gene with both early and late transcription start sites (*gp67*) and a gene with only a late promoter (*chiA*). When production of these proteins was compared in *Aclef-2.5'c-myc-* or AcMNPV-infected cells, no differences in temporal synthesis or accumulation were observed (Fig. 5). It was interesting to note, however, that LEF-4 declined in abundance from about 12 h p.i.

Immunodetection of the C-MYC-tagged-LEF-2 in infected cells

Insect cells infected with *Aclef-2.c-myc5'* were examined using Western blot analysis in conjunction with the C-MYC-specific monoclonal antibody (9E10) to detect the tagged-LEF-2 (Fig. 6A). A specific product of approximately 25 KDa was detected in *Aclef-2.c-myc5'*-infected cells. The size of this product was consistent with the predicted combined molecular weights of LEF-2 (23.9 kDa; Ayres *et al.*, 1994) and C-MYC (1.6 kDa). The protein was first detected weakly at 4 h p.i. and increased in abundance until 24 h.p.i., the last point tested. In AcMNPV-infected cells, the 25 kDa protein was not detected (Fig. 6B). In both experiments a major extra band, around 35 KDa, was detected even in

the mock-infected lane. This corresponded to a cross reaction of our antibody against a host protein.

It was predicted that LEF-2 would be localised in the nuclei of virus-infected cells. It is associated with both DNA replication and late gene transcription. Both biochemical fractionation and immunofluorescence microscopy were used to test this hypothesis. Only the confocal microscopy observations are shown in Figure 7. Staining was found mainly in the nucleus of infected cells at both 9 and 24 hr p.i. The staining appeared to be concentrated in a central area that seemed to match the virogenic stroma. At early times after virus-infection (9 hr p.i.), the staining was observed as small discrete areas (foci) in the nucleus. Later in virus infection (24 hr p.i.) a large central area was stained. These results indicated that LEF-2 localised in the nucleus at both early and late times post infection.

Construction of a recombinant baculovirus with a bacterial origin of replication

A recombinant virus was constructed (Acp10Bac), which contained a bacterial origin of replication and chloramphenicol resistance gene inserted at the p10 locus within AcMNPV. This was amplified in Sf21 cells and used to isolate virus genomic DNA. The Acp10Bac DNA was used to transform DH10B cells via electroporation. Successful transformants were selected by growth on LB-agar plates containing chloramphenicol. Colonies of bacteria were amplified in liquid medium containing the same antibiotic and used to isolate virus genomic DNA. This DNA was used to transfect Sf21 cells. Three days after transfection cytopathic effects (cpe) were observed in the virus-infected cells. The virus-infected cell culture medium was harvested after seven days and the titre of the infectious virus determined using a plaque assay in Sf21 cells. The titre of the virus was 5×10^7 plaque forming units (pfu) per ml.

Construction of BacPAK6 with a bacterial origin of replication

The construction of Acp10Bac demonstrated that it was feasible to insert a bacterial origin of replication into AcMNPV and produce a virus genome, which could be maintained as an

episome in bacteria. The virus DNA could also be recovered from bacteria and used to transfect insect cells to reinitiate infection in the normal host. To make further manipulations of the baculovirus genome simpler, the polyhedrin gene within Acp10Bac was replaced with a copy of the beta-galactosidase gene (*lacZ*) from *E. coli*. This was achieved by cotransfecting insect cells with Acp10Bac DNA, derived from virus particles, with the transfer vector pBacPAK6 (Kitts and Possee, 1993). Recombination between the homologous sequences within the virus and plasmid resulted in the insertion of the *lacZ* into the polyhedrin locus of Acp10Bac to derive BacPAK6p10Bac. This virus was isolated by titration of the virus produced in the cotransfection by plaque assay in Sf21 cells. Virus plaques, which lacked polyhedra but stained blue in the presence of X-gal, were selected for further amplification in the same host cells. Genomic DNA was isolated from purified BacPAK6p10Bac virus particles and used to transform DH10B cells to confirm that the bacterial replication origin and antibiotic selection components were still functional.

Construction of a recombinant virus lacking genes essential for virus replication

BacPAK6p10Bac was modified to determine if removing a portion of the virus genome containing genes thought to be essential for virus replication prevented infection of insect cells. The region of the virus genome, which was chosen, was immediately downstream of the normal position of the polyhedrin gene (ca. 5050 - 12,000 base pairs; Ayres *et al.*, 1994). This contains ORF1629, protein kinase 1 and *lef-1*, genes that are probably required for virus replication and several other putative genes of unknown function. To remove this region from the virus genome, an extra *AvrII* site was inserted within the 3' end of the ORF1629 coding region in the plasmid transfer vector pAcAL1 (King and Possee, 1992). This modification (Figure 8), resulted in a conservative amino acid change within the predicted polypeptide sequence of ORF1629. The modified transfer vector pAcAL1-*AvrII*, was mixed with BacPAK6p10Bac genomic DNA, which had been linearised with *Bsu36I* and used to cotransfect Sf21 cells. The progeny virus was titrated in a plaque assay and plaques that remained white in the presence of X-gal were isolated (AL1*AvrII*). These were amplified in insect cells to provide working virus stocks, which were then used to derive virus genomic DNA. The virus genomic DNA was digested with *AvrII* and analysed using agarose gel electrophoresis. This showed that a 6385 bp fragment was excised from

the virus genome after digestion with the restriction enzyme, as a consequence of DNA cleavage with *AvrII* within the ORF1629 and a native *AvrII* site within *egt*.

Religation of the *AvrII*-digested AL1*AvrII* and subsequent transfection of Sf21 cells failed to generate a virus that lacked the 6385 bp fragment generated by digestion with *AvrII*; only parental, undigested AL1*AvrII* was able to replicate. However, because replication of virus DNA in bacterial cells did not depend on these sequences, it was possible to transform DH10B with *AvrII*-digested, religated DNA to generate chloramphenicol-resistance colonies on appropriate agar selection plates. DNA isolated from amplified colonies could not initiate infection when it was used to transfect Sf21 cells. However, when it was mixed with pAcBgIII-C, a plasmid containing a region of the AcMNPV genome overlapping the portion deleted from AL1*AvrII*, a productive infection was established in these cells. This was consistent with rescue of the defective form of AL1*AvrII* by recombination with the homologous regions in pAcBgIII-C, thus replacing the virus genes that had been removed.

These results demonstrated that a defective form of AcMNPV DNA could be maintained in a bacterial system, purified and used to regenerate infectious virus by cotransfection with a rescuing plasmid. If the rescue plasmid contained a foreign gene, it would be an ideal way to make a recombinant virus for heterologous protein production. The plasmid used for the rescue experiment was pAcBgIII-C, which is 15150 bp. This is too large to use as a transfer vector for carrying foreign genes. Most baculovirus transfer vectors used to insert foreign genes into the virus genome are smaller (5.0 – 10.0 kbp) and unsuitable for the rescue of the deletion within AL1*AvrII*. It was necessary, therefore, to construct a defective baculovirus genome, maintained in bacterial cells, with a smaller deletion that could be rescued by available plasmid transfer vectors.

Construction of a recombinant virus lacking part of ORF1629

The ORF1629 encodes a protein, which forms part of the virus nucleocapsid (Vialard and Richardson, 1993). Earlier work (Possee *et al.*, 1991) showed that it probably could not be removed from the virus genome. This hypothesis was tested by constructing BacPAK6, which contained three *Bsu36I* sites, so permitting the removal of part of the ORF1629

coding region (Kitts and Possee, 1993). When BacPAK6 was digested with *Bsu36I*, infectious virus could only be obtained if the linear virus DNA was mixed with a plasmid transfer vector prior to cotransfection of insect cells. The transfer vector restored ORF1629 function and facilitated virus replication. This is the principle of making recombinant viruses using linearised virus DNA. If the defective form of the virus DNA could be amplified in a heterologous system it would enable recombinant virus production without parental virus contamination.

The recombinant virus, BacPAK6p10Bac, which contains the bacterial origin of replication and chloramphenicol resistance gene, was digested with *Bsu36I* to remove part of ORF603, *lacZ* and the 3' coding region of ORF1629. The restriction enzyme left asymmetric ends, which were incompatible for subsequent ligation. Consequently, the DNA ends were repaired with the large sub-unit of the *E. coli* DNA polymerase 1 (Klenow) prior to ligation to create a circular molecule, lacking ORF603, *lacZ* and part of ORF1629. The ligation mixtures were used to transform *E. coli* DH10B cells and derive chloramphenicol-resistant colonies on agar plates. These were designated AcORF1629-3'. Colonies were isolated, amplified in liquid cultures and virus DNA purified. When this DNA was used to transfect Sf21 cells in the absence of a rescuing plasmid, virus replication was not detected. However, when a baculovirus plasmid transfer vector, containing a copy of the *lacZ* coding region under the control of the polyhedrin gene promoter, was mixed with AcORF1629-3' DNA prior to cotransfection of insect cells, a cpe was observed at 4 days p.i. When X-gal was added to the virus-infected cells, they turned blue after overnight incubation at 28°C. The progeny virus was harvested at 7 days p.i. and titrated in a plaque assay. When these plaques were stained with X-gal at 4 days p.i., all of them were blue. This indicated that every virus recombinant produced after cotransfection of insect cells with AcORF1629-3' and a plasmid transfer vector contained a foreign gene.

DISCUSSION

In this study, we used *S. cerevisiae* as a host to maintain the AcMNPV genome and permit the manipulation of *lef-2*, a gene that is essential for replication of the virus in insect cells (Passarelli and Miller, 1993). The method was adapted from a protocol developed for the production of recombinant viruses containing foreign genes, that eliminated the need for plaque purification (Patel *et al.*, 1992). We retained the AUC elements, inserted in lieu of the AcMNPV polyhedrin gene, to facilitate DNA replication in yeast cells. Part of the *lef-2* coding region was replaced with *sup4-o* within a transfer vector. This plasmid was then introduced into yeast cells harbouring the AcMNPV genome to effect the modification of *lef-2* via homologous recombination. Although *lef-2* was targeted in this study, the method could be readily adapted to modify any baculovirus gene. It should circumvent the difficulties frequently encountered when trying to inactivate virus-coding regions by insertion of a reporter gene such as *lacZ* after cotransfection of insect cells with virus DNA and a transfer vector. If the target sequence is essential for virus replication, recombinant viruses are unstable and rapidly lost from the population. This problem was encountered when trying to modify the AcMNPV ORF1629 (Possee *et al.*, 1991), which encodes a nucleocapsid-associated protein (Vialard and Richardson, 1993). The failure to isolate a recombinant virus was indicative, but not satisfactory evidence that this gene cannot be deleted from the virus genome.

The product of *lef-2* (Passarelli and Miller, 1993) has a key role in viral replication. It was originally shown to be required for DNA replication (Kool *et al.*, 1994; 1995; Lu and Miller, 1995; Lu *et al.*, 1997). This conclusion derived from experiments where the transient replication of a reporter plasmid in the presence or absence of a number of baculovirus genes was measured. Although a very powerful system, its design precludes the identification of other roles for these genes in events subsequent to DNA replication. In other studies it was suggested that LEF-2 could also be involved directly in the regulation of very late gene expression, via the use of a virus with a mutation within the gene (Merrington *et al.*, 1996) or anti-sense inhibition of its transcription (Sriram and Gopinathan, 1998). Clearly, there is scope for alternative approaches to studying the functions of this protein.

The recombinant virus DNA (*AcΔ.lef-2.sup4-o*) from yeast, with a deletion in *lef-2*, was unable to transfect *Sf21* cells. This provided unambiguous evidence that *lef-2* is required for propagation of the virus in insect cells. However, co-transfection of this DNA with a plasmid containing an unmodified copy of *lef-2* permitted the recovery of infectious virus. This showed that no other mutation within the *AcΔ.lef-2.sup4-o* genome was responsible for the failure of the virus to replicate in insect cells. In future studies, it should be possible to co-transfect insect cells with *AcΔ.lef-2.sup4-o* DNA and plasmids containing selected modifications to *lef-2*. This would enable the function of each domain of the protein to be dissected *in vivo*, as judged by the failure or otherwise to regenerate an infectious virus. Incorporating a suitable reporter gene under early or late promoters into the system would also allow direct measurements of virus gene expression at different times after infection.

Some technical problems were noted during the use of the yeast system. Viral DNA extracted from yeast was not very efficient at establishing an infection when used to transfect *Sf21* cells. Once the primary infection was established, however, virus stocks of normal titre could be obtained after subsequent passage in the same cells. This is probably due to the procedure used to extract the DNA from the yeast cells. The method is protracted and employs phenol extraction and ethanol precipitation to purify total DNA from the cells. It has previously been noted that precipitation of viral DNA reduces infectivity, due to the inevitable shearing that results on resuspension (King and Possee, 1992). The low infectivity of the viral DNA from yeast may, therefore, be due to only a subpopulation of the DNA remaining as intact circles.

A low number of yeast colonies were obtained on transformation of the strain carrying the intact *AcMNPV* genome with the transfer vector containing the *sup4-o* gene. This may have been due to either a low recombination frequency or the action of the *sup4-o* gene product itself. When the yeast cells were transformed with the *sup4-o*-containing transfer vector, recombination was required to permit insertion of the *sup4-o* gene in place of *lef-2*. The efficiency of this recombination has not been estimated in yeast cells. It has been noted that, in insect cells, recombination occurs at a frequency of between 0.1 and 1%. A low frequency of recombination would lead to the production of only a few *sup4-o*⁺ colonies.

Alternatively, the *sup4-o* gene encodes an ochre-suppressing tRNA. The ochre suppression may be a more stringent selection than an auxotrophic marker. We are currently investigating the use of alternative markers as insertable elements.

It was found that nine out of the twelve *sup4-o*-containing colonies produced virus DNA that was able to infect insect cells irrespective of the presence of the rescuing plasmid. This may have been due to the *sup4-o* gene inserting at alternate loci in the viral genome, causing no effect on virus replication. The *sup4-o* gene may also have inserted into the yeast chromosome itself, as it is known that only very short sequences are required for homologous recombination in yeast. We are currently working to improve the number of positive recombinants obtained.

We also used Δ *lef-2.sup4-o* DNA as an intermediate step in the construction of a virus with an antigenic tag at the extremities of the protein. Tags are short polypeptide sequences for which we possess powerful monoclonal antibodies that facilitate identification and purification of the protein, even if it is present in low levels in the cells. In this example, the tagging procedure was successful only at the N terminal of LEF-2, suggesting that the C-terminal end is a critical position for the function of the protein. Recently, the Asp residue (D178) in the C-terminal of the protein was associated with the regulation of very late gene expression (Merrington *et al.*, 1996). In addition, it has been noticed that the C-terminal domain is a cysteine rich area that presents structural homology with proteins, such as Adenovirus p300/CBP, involved in gene regulation (Eckner *et al.*, 1994). Therefore it seems likely that modification of the C terminal end of LEF-2 cannot be tolerated because of a crucial role in its function.

Gene expression was compared in cells infected with AcMNPV or *Aclef-2c-myc5'*, to determine if the addition of the tag to LEF-2 had any effect on transcription. Transcription analysis of *lef-2* in AcMNPV and *Aclef-2c-myc5'*-infected cells showed no differences between the two viruses. In both viruses, a dual promoter included within the 350 nucleotides upstream of the ATG drove the expression of *lef-2*. The *lef-2* transcripts were detected as early as 1 hr p.i. and reached a high level by 48 hr p.i. The early start site was mapped at a C within the sequence CAATGCGCCCGTTGT localised 279 nt upstream of

the *lef-2* ATG. A TATA-like sequence was evident between 35 and 30 nucleotides upstream from the transcription initiation site, confirming the cellular structure of this promoter. The late start site was mapped within the characteristic sequence TAAG located 361 nucleotides upstream of the start codon. Similar sites were recently found for the closely related BmNPV *lef-2* (Sriram and Gopinathan, 1998). Identifying the polyadenylation anchor site 17 nucleotides downstream from the *lef-2* translation stop codon completed the transcriptional analysis. The production of LEF-4, GP64 and chitinase was studied to determine that the addition of the C-MYC tag to LEF-2 did not have subtle effects on early and late virus gene expression. We concluded that the modification to *lef-2* was neutral with respect to virus replication.

Using an antibody against the C-MYC epitope, the kinetics of LEF-2 production was analysed. The protein, with an expected size of 25 kDa, was first detected four hours after infection. Its quantity increased during the late phase of the infection. This result was in agreement with the RNA concentration during the viral cycle. However, the level of expression was found to be quite low even though a late promoter was involved in the transcription of the *lef-2*. Recent data suggested the importance of the sequence directly upstream from the TAAG motif for the selection and the level of expression of a late promoter (Mans and Knebel-Mörsdorf, 1998). Reduced helix stability was found to correlate with functional TAAG motifs. In the case of the *lef-2* late promoter, the upstream sequence was sufficiently A/T-rich to create a functional late promoter but not high enough to derive a strong late promoter. This observation may explain the results obtained for the LEF-2 production. Due to the low level of *lef-2* expression, the detection of the protein by a classic indirect immuno-fluorescence was impossible with our anti-c-myc antibody. We improved the sensitivity of detection using an amplification method which consisted of incubating fixed cells twice with primary and secondary antibodies. We observed a nuclear localisation of LEF-2 at both early and late times post infection. This was consistent with roles for the protein in both DNA replication and late virus gene expression. Others antibodies obtained against the complete LEF-2 over produced in bacteria or against synthetic peptides failed to detect efficiently the protein in both western blot and indirect immunofluorescence microscopy, revealing the poor antigenic character of the protein. These results, or lack of them, validate the approach of using a well-defined epitope and

appropriate antibody for the detection of such proteins. The method should be applicable to any protein that is expressed at a low level in baculovirus-infected cells and presents difficulties in raising an antiserum.

The insertion of a bacterial origin of replication and chloramphenicol resistance gene at the p10 locus in AcMNPV (Acp10Bac) enabled virus DNA amplification within bacteria. Virus DNA recovered from these bacteria was able to transfect insect cells and regenerate infectious virus progeny. These results were consistent with the observations made by Luckow *et al* (1993), that baculovirus genomes could be maintained in *E. coli*. Their experiments were based on earlier studies, which showed that 300 kbp bacterial artificial chromosomes (Bacs) could be maintained in *E. coli* (REF). The propagation of such large DNA molecules in bacterial cells has been essential for the rapid progress made in the sequencing of the complete human genome and other species.

We extended our results further by constructing a baculovirus mutant (AL1A ν rII) lacking at least three genes (ORF1629, protein kinase 1 and *lef-1*) thought to be required for replication in insect cells. This virus genome was maintained in bacterial cells since it was incapable of replication in Sf21 cells, as demonstrated after transfection of these cells with AL1A ν rII DNA. However, when the virus DNA was mixed with pAcBgII-C, which spans the region missing from AL1A ν rII, prior to cotransfection of insect cells, infectious virus was recovered and amplified to normal titres.

These results demonstrated the principle of our invention, that non-infectious baculovirus DNA could be rescued by cotransfection with a suitable plasmid. They were extended by constructing another AcMNPV mutant (AcORF1629-3'), which lacked only a small region of the 3' coding region of ORF1629. This virus DNA could be mixed with a baculovirus transfer vectors used to make recombinant viruses and cotransfected into insect cells to make infectious virus. We used a rescuing plasmid (pBacPAK6) which contained a copy of the *lacZ* gene under the control of the polyhedrin gene promoter, but any similar vector could be used. The advantage of our system is that most baculovirus transfer vectors, compatible with the polyhedrin gene locus, can be used to make recombinant virus.

The major feature of our system is that there is no contamination of the recombinant virus preparation with parental virus. This means that plaque assays subsequent to the original transfection do not have to be performed. Our new method for making recombinant baculoviruses is compared with the Bac-to-Bac and linear DNA methods currently widely used by research laboratories and Pharmaceutical companies. It offers a saving in time of several days over both methods and significantly decreases the number of manipulations required to make a recombinant virus.

Both of the viruses (AL14vrII and AcORF1629-3') made in this study had the bacterial replicon inserted at the p10 gene locus. Although this is not a problem, it does leave extra sequences in the recombinant virus after the DNA is rescued with a plasmid transfer vector in Sf21 cells. Therefore, we propose to make a second generation of viruses, which have the bacterial replicon inserted at the polyhedrin gene locus. These viruses will also be unable to replicate in insect cells, because part of ORF1629 will be missing. They will represent an advance over the viruses made in this study, because the foreign gene from the rescuing transfer vector will replace the bacterial replicon as recombination takes place in insect cells.

We also anticipate that this new method could be adapted for use in 96-well (or greater) multi-well microtitre plates. The use of a robotic device to manipulate reagents would make it feasible to generate very large numbers of recombinant baculoviruses very quickly and without a large input of labour. It might be possible to coat the wells of such plates with the baculovirus DNA so that it could be resuspended prior to use by adding appropriate buffer containing the plasmid transfer vector, then adding lipofectin to mediate the formation of DNA-lipid complexes before adding insect cells to initiate cotransfection. This would form the basis of a very convenient kit for making recombinant baculoviruses.

The results show that it is possible to rescue replication-deficient virus using a rescue vector encoding a gene encoding a protein for restoring replication. The inventors have realised that it is possible to take this a step further by inserting a foreign gene into the rescue vector. The foreign gene may then be recombined with the baculovirus at the same

time as the gene for restoring replication. Such a recombinatorial event can be selected for because the recombined virus containing the foreign gene will be able to replicate.

09807803 071001
T00E20" 60820860

REFERENCES

Ahrens, C. H. & Rohrmann, G. F. (1995). Identification of essential trans-acting regions required for DNA replication of the *Orgyia pseudotsugata* baculovirus multinucleocapsid nuclear polyhedrosis virus: *lef-1* is an essential replication gene. *Virology* **207**, 417-428.

Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. (Struhl, K. (1994). *Current Protocols in Molecular Biology*. Wiley, New-York.

Ayres, M. D., Howard, S. C., Kusio, J., López-Ferber, M. (Possee, R. D. (1994). The complete DNA sequence of *Autographa californica* nuclear polyhedrosis virus. *Virology* **202**, 586-605.

Blissard, G. W. (Rohrmann, G. F. (1989). Location, sequence, transcriptional mapping, and temporal expression of the *gp64* envelope glycoprotein gene of the *Orgyia pseudotsugata* multicapsid nuclear polyhedrosis virus. *Virology* **170**, 537-555.

Durantel, D., Croizier, L., Ayres, M. D., Croizier, G., Possee, R. D. & López-Ferber, M. (1998a). The *pnk/pnl* gene (ORF 86) of *Autographa californica* nucleopolyhedrovirus is a non essential, immediate early gene. *J. Gen. Virol.* **79**, 629-637.

Durantel, D., Croizier, G., Ravallec, M. & López-Ferber, M. (1998b). Temporal expression of the *AcMNPV lef-4* gene and subcellular localisation of the protein. *Virology* **241**, 276-284.

Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., Decaprio, J. K., Lawrence, J. B. & Livingston, D. M. (1994). Molecular cloning and functional analysis of the adenovirus associated 300 kD protein (p300) reveals a protein with properties of a transcription adaptor. *Genes Dev.* **8**, 869-884.

Evan, G.I., Hancock, D.C., Littlewood, T. & Pauza, C.D. (1986). Characterization of the human c-myc protein using antibodies prepared against synthetic peptides. *Ciba Found Symp* **119**, 245-263.

Evans, J. T., Leisy, D. J. & Rohrmann, G. F. (1997). Characterisation of the interaction between the baculovirus replication factors LEF-1 and LEF-2. *J. Virol.* **71**, 3114-3119.

Fan, X., MacLachlin, J. R. & Weaver, R. F. (1998). Identification and characterisation of a protein kinase-interacting protein encoded by the *Autographa californica* Nuclear polyhedrosis virus. *Virology* **240**, 175-182.

Fan, X., Thirunavukkarasu, K. & Weaver, R. F. (1996). Temperature-sensitive mutations in the protein kinase-1 (*pk-1*) gene of the *Autographa californica* nuclear polyhedrosis virus that block very late gene expression. *Virology* **224**, 1-9.

Fitzgerald-Hayes, M. (1987). Yeast centromeres. *Yeast* **3**, 187-200.

Funk, C. J., Harwood, S. H. & Rohrmann, G. F. (1998). Differential stability of baculovirus late transcription complexes during initiation and elongation. *Virology* **241**, 131-140.

Gomi, S., Ecale Zhou, C., Yih, W., Majima, K. and Maeda, S. (1997). Deletion analysis of eighteen late expression factor gene homologues of the baculovirus BmNPV. *Virology* **230**, 35-47.

Goodman, H. M., Olson, M. V. & Hall, B. D. (1977). Nucleotide sequence of a mutant eukariotic gene: the yeast tyrosine inserting ochre suppressor *sup4-o*. *Proc. Natl. Acad. Sci. U.S.A.* **74**, 5453-5457.

Graham, F.L. and Vander Eb A.J. (1973). *Virol.* **52**, 456.

Guarino, L. A., Xu, B., Jin, J. & Dong, W. (1998). A virus-encoded RNA polymerase purified from baculovirus infected cells. *J. Virol.* **72**, 7985-7991.

Hawtin, R. E., Arnold, K., Ayres, M. D., Zanotto, P. M. A., Howard S. C., Gooday, G. W., Chappel, L. H., Kitts, P. A., King, L. A. & Possee, R. D. (1995). Identification and preliminary characterisation of a chitinase gene in the *Autographa californica* nuclear polyhedrosis virus genome. *Virology* **212**, 673-685.

Ito, H., Fukuda, Y., Murata, K. & Kimura, A. (1983). Transformation of intact yeast cells treated with alkali cations. *J. Bacteriol.* **153**, 163-168

King, L. A. & Possee, R. D. (1992). "The Baculovirus Expression System. A Laboratory Guide," first ed. Chapman and Hall, London.

Kitts, P.A. and Possee, R.D. (1993). A method for producing recombinant baculovirus expression vectors at high frequency. *Biotechniques* **14**, 810-817.

Kool, M., Ahrens, C. H., Vlak, J. M. & Rohrmann, G. F. (1995). Replication of baculovirus DNA. *J. Gen. Virol.* **76**, 2103-2118.

Kool, M., Ahrens, C., Goldbach, R. W., Rohrmann, G. F. & Vlak, J. M. (1994). Identification of genes involved in DNA replication of the *Autographa californica* baculovirus. *Proc. Natl. Acad. Sci. U.S.A.* **91**, 11212-11216.

Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.

Lu, A., Krell, P. J., Vlak, J. M. & Rohrmann, G. F. (1997). Baculovirus DNA replication. In: *The baculoviruses* (Miller, L. K., ed.) p. 171-192. Plenum press, New-York.

Lu, A. & Miller, L. K. (1995). The role of eighteen baculovirus late expression factor genes in transcription and DNA replication. *J. Virol.* **69**, 975-982.

Lu, A. & Miller, L. K. (1994). Identification of three late expression factor genes within the 33.8- to 43.3-map unit region of *Autographa californica* nuclear polyhedrosis virus. *J. Virol.* **68**, 6710-6718.

Lu, A. & Miller, L. K. (1997). Regulation of baculovirus late and very late gene expression. In: *The baculoviruses* (Miller, L. K., ed.) p.193-216. Plenum press, New-York.

Luckow, V.A., Lee, S.C., Barry, G.F. and Olins, P.O. (1993). Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in *Escherichia coli*. *J. Virol.* **67**, 4566-4579.

McLachlin, J. R., Yang, S. & Miller L. K. (1998). A baculovirus mutant defective in PKIP, a protein which interacts with a virus-encoded protein kinase. *Virology* **246**, 379-391.

McLachlin, J. R. & Miller L. K. (1994). Identification and characterization of *vlf-1*, a baculovirus gene involved in very late gene expression. *J. Virol.* **68**, 7746-7756.

Merrington, C. L., Kitts, P. A., King, L. A., and Possee, R. D. (1996). An *Autographa californica* nucleopolyhedrovirus *lef-2* mutant: Consequences for DNA replication and very late gene expression. *Virology* **217**, 338-348.

Newman, A. and Norman, C. (1991). Mutations in yeast U5 snRNA alter the specificity of 5' splice-site cleavage. *Cell* **65**, 115-123.

Passarelli, A. L. & Miller, L. K. (1993a). Three baculovirus genes involved in late and very late gene expression: *ie-1*, *ie-N*, and *lef-2*. *J. Virol.* **67**, 2149-2158.

Patel, D., Nasmyth, K. & Jones, N. (1992). A new method for the isolation of recombinant baculovirus. *Nucleic Acids Res* **20**, 97-104.

Stinchcomb, D. T., Struhl, K. & Davis, R. W. (1979). Isolation and characterisation of a yeast chromosomal replicator. *Nature* **282**, 39-43

Todd, J. W., Passarelli, L. A. & Miller, L. K. (1995). Eighteen baculovirus genes, including *lef-11*, *p35*, *39k*, and *p47*, support late gene expression. *J. Virol.* **69**, 968-974.

Todd, J. W., Passarelli, L. A. & Miller, L. K. (1996). Factors regulating baculovirus late and very late gene expression in transient-expression assays. *J. Virol.* **70**, 2307-2317.

Vilard, J.E. and Richardson, C.D. (1993). The 1629-nucleotide open reading frame located downstream of the *Autographa californica* nuclear polyhedrosis virus polyhedrin gene encodes a nucleocapsid-associated phosphoprotein. *J. Virol.* **67**, 5859-5866.

Weyer, U. and Possee, R.D. (1988). Functional analysis of the p10 gene 5' leader sequence of the *Autographa californica* nuclear polyhedrosis virus. *Nucleic Acids Research* **16**, 3635-3653.

Weyer, U., Knight, S. and Possee, R.D. (1990). Analysis of very late gene expression by *Autographa californica* nuclear polyhedrosis virus and the further development of multiple expression vectors. *Journal of General Virology* **71**, 1525-1534.

Wigler, M. *et al.* (1977) *Cell*. **11**, 223.

Yang, S. & Miller, L. K. (1998a). Expression and mutational analysis of the baculovirus very late factor 1 (*vlf-1*) gene. *Virology* **245**, 99-109.

Yang, S. & Miller, L. K. (1998b). Control of baculovirus polyhedrin gene expression by very late factor 1. *Virology* **248**, 131-138.

Claims


1. Method for cloning a gene comprising the steps of:
 - (i) Providing a replication-deficient baculovirus vector;
 - (ii) Providing a rescue vector encoding:
 - (a) a nucleic acid sequence which is capable of restoring replication in the replication-deficient baculovirus vector; and
 - (b) at least one gene to be cloned.
 - (iii) Causing the replication-deficient baculovirus vector and rescue vector to recombine to produce a replication-enabled baculovirus vector comprising the at least one gene to be cloned; and
 - (iv) Growing the replication-enabled baculovirus vector within a suitable invertebrate cell.
2. Method according to claim 1, wherein the invertebrate cell is an insect cell.
3. Method according to claim 1 or claim 2, wherein the replication-deficient baculovirus vector lacks a functional gene necessary for viral replication and the rescue vector comprises a gene necessary for restoring the functional gene.
4. Method according to claim 3, wherein the functional gene is selected from *lef-1*, *lef-2*, *lef-3*, *lef-4*, *lef-5*, *lef-6*, *lef-7*, *lef-8*, *lef-9*, *lef-10*, *lef-11*, *lef-12*, *dnapol*, *p143*, *p35*, *ie-1*, *ie-2*, *p47*, *ORF1629* and *pp31*, or a functional fragment or mutation thereof.
5. Method according to claim 4, wherein the functional gene is *lef-2* or a functional fragment or mutation thereof.
6. A method according to any preceding claim wherein the replication deficient baculovirus vector is capable of being maintained in an intermediate host.
7. A method according to claim 6, wherein the intermediate host is a yeast cell or a bacterial cell.

8. A method according to claim 6 or claim 7, wherein the replication deficient baculovirus vector comprises one or more nucleic acid sequences which enable the vector to replicate within the intermediate host.
9. A method according to any preceding claim wherein the recombination step (iii) takes place within the invertebrate cell.
10. A method according to any preceding claim, additionally comprising the step of (v) growing invertebrate cell so that the or each foreign gene is expressed within the cell.
11. A replication deficient baculovirus vector for use in a method according to any preceding claim.
12. A vector according to claim 11, additionally comprising one or more nucleic acid sequences which enable the vector to replicate within an intermediate host.
13. A vector according to claim 12, wherein the vector comprises one or more nucleic acid sequences selected from ARS-1, CEN-1 and a bacterial origin of replication (*ori*).
14. A vector according to any one of claims 11 to 13, in which at least a part of the naturally occurring polyhedrin gene has been deleted.
15. A vector according to any one of claims 11 to 14, wherein the vector is based upon *AcMNPV*.
16. A rescue vector for use in a method according to any one of claims 1 to 10 comprising (a) a nucleic acid sequence which is capable of restoring replication in a replication-deficient baculovirus, and (b) at least one site for insertion of a gene to be cloned.
17. A rescue vector according to claim 16, wherein the site for insertion of the gene to be cloned is operably linked to regulatory elements necessary for expression of said gene.


18. A rescue vector according to claim 17, wherein the site for insertion of the foreign gene is operably linked to a promoter selected from a baculovirus polyhedrin promoter or a baculovirus p10 promoter.
19. An intermediate host cell comprising a replication-deficient baculovirus vector according to any one of claims 11 to 15.
20. A cell comprising a rescue vector according to any one of claims 16 to 18.
21. An invertebrate cell obtainable by a method according to any one of claims 1 to 10.
22. A kit for use in a method according to any one of claims 1 to 10 comprising a replication deficient vector according to any one of claims 11 to 15.
23. A kit according to claim 22 additionally comprising a rescue vector according to any one of claims 16 to 18.
24. A kit for use in a method according to any one of claims 1 to 10 comprising a rescue vector according to any one of claims 16 to 18.
25. A kit according to any one of claims 22 to 24 additionally comprising one or more buffers, preservatives or stabilising agents.
26. An isolated nucleic acid molecule consisting of a sequence selected from:
AAATTCAGATATAAAGACGCTGAAAATCATTG,
TGATTTTCAGCGTCTTTATATCTGAATTT,
ATTTTCGCTCTAACATAACCACCCTAGGGATGTAC,
GTACATCCCTAGGGTGGTATGTTAGAGCGAAAATCAAA,
CTAGGGATTATAAATTTAATGAATTATTAAAATAC,
GTATTTTAATAATTCATTAAATTTATAATCC.

Figure 1

(a) AcMNPV



(b) AcAUC



(c) AcΔlef-2.sup4-o




Figure 2




Figure 3





Figure 4







Figure 6







Figure 7

Figure 8.



DECLARATION AND POWER OF ATTORNEY

Attorney's Docket No. 23890-257438
(46309-257438)In re Application of: **BACULOVIRUS EXPRESSION SYSTEM**
As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **BACULOVIRUS EXPRESSION SYSTEM**, the specification of which:

☒ was filed on April 18, 2001 as Application No. 09/807,809 (if applicable) and was amended on April 18, 2001.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used by others in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to the date of this application. I further state that the invention was not in public use or on sale in the United States of America more than one year prior to the date of this application. *I understand that I have a duty of candor and good faith toward the Patent and Trademark Office*, and I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of the foreign application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate disclosing subject matter in common with the above-identified specification and having a filing date before that of the application on which priority is claimed:


Application No.	Country	Filing Date	Priority Claimed Under 35 USC §119
PCT/GB00/03144	PCT	14 August 2000	Yes <u>X</u> No _____
GB99/19409.4	GB	18 August 1999	Yes <u>X</u> No _____

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

POWER OF ATTORNEY: The following attorneys are hereby appointed to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Customer Number 23594

Direct all correspondence to: Customer Number 23594


AFFIX BAR
CODE LABEL →
HERE



Direct telephone calls at 404-949-3999, to John K. McDonald, Ph.D.

Full name of sole or first inventor: Robert David Possee	Citizenship: United Kingdom
Inventor's signature: <u>[Signature]</u>	Date: <u>15/7/01</u>
Residence and Post Office Address: 8 Hurdswell, Long Hanborough, Witney, Oxon. OX3 0BP, United Kingdom	<u>GBN</u>
Full name of second inventor, if any: Linda Anne King	Citizenship: United Kingdom
Inventor's signature: <u>[Signature]</u>	Date: <u>14/7/01</u>
Residence and Post Office Address: 8 Hurdswell, Long Hanborough, Witney, Oxon. OX3 0BP, United Kingdom	

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. Drawings

09807809 60820850